RxDoctor Payments Data

Christal Murray, MD

Hematology & Oncology · Round Rock, TXNPI 1518079581

Payments from drug & device makers

$515,594in general payments, 2019–2025

Across 71 payments — averaging $7261.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$214K
  • Pfizer$160K
  • Acerta Pharma LLC$108K
  • Sanofi US Services Inc.$21K
  • Bristol Myers Squibb$12K
  • Myriad Genetic Laboratories, Inc.$436
  • plus $578 from 6 others
$11,669in research payments, 2019–2025

Across 2 payments — averaging $5834.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K

What the payments were for

  • Grants$35035%
  • Food & beverage$62962%
  • Education$353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515,594 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$108,427
Medicare patients
456
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate27$500,606
KisqaliRibociclib Succinate28$446,422
IbrancePalbociclib26$396,914
CalquenceAcalabrutinib Maleate15$237,898
XtandiEnzalutamide12$169,241
EliquisApixaban57$46,894
Anastrozole676$19,271
Exemestane56$9,283
Tamoxifen Citrate219$6,593
Letrozole91$2,380
Ibandronate Sodium57$2,008
ValacyclovirValacyclovir Hcl13$1,010
Hydroxyurea33$758
Dexamethasone39$675
Gabapentin44$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$159,908$443,80883 claims
AstraZenecaCalquence$350$237,89815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →